Get comprehensive updates on ongoing clinical trials across biotech, medtech, and pharma. Learn about groundbreaking studies and research findings that are setting the stage for future FDA approvals and new treatments.
Quick Summary •Setback: Neurogene reported an adverse event in its high-dose gene therapy trial for Rett syndrome, involving liver toxicity and immune responses. •Key Issue:
Quick Summary Event: Neurogene’s stock fell 44% after reporting a severe adverse event in its high-dose gene therapy trial for Rett syndrome. Clinical Concern: The
Quick Summary Clinical Data: Viking Therapeutics reported positive weight-loss results from trials of its oral obesity drug candidate. Market Reaction: Despite the positive clinical data,
Quick Summary Drug Development: Novo Nordisk plans to expand its obesity drug’s applications to treat metabolic-associated steatohepatitis (MASH). Clinical Findings: New trials indicate the drug’s
Quick Summary Therapy: Apitegromab, a muscle-targeted monoclonal antibody Trial Outcome: Significant improvements in motor function for non-ambulatory SMA patients Regulatory Plans: Scholar Rock intends to
Quick Summary Trial Result: Eli Lilly’s Taltz (ixekizumab) outperformed Janssen’s Tremfya (guselkumab) in a head-to-head Phase IV study. Primary Outcome: 41% of patients treated with
Quick Summary Key Result: Intellia Therapeutics reports up to an 81% reduction in angioedema attacks for high-dose recipients in its Phase 2 trial. Therapeutic Potential:
Quick Summary Trial Outcome: Boston Scientific’s Acurate neo2 transcatheter aortic valve replacement (TAVR) system missed its primary endpoint in a critical trial. Comparison Results: Acurate
Novartis’ €2.7 Billion Investment in MorphoSys Hits Setback as Safety Signal Delays Key Drug Filing Novartis’ recent acquisition of MorphoSys aimed to bring promising therapies
Personalized medicine, also known as precision medicine, is transforming the landscape of cancer treatment by tailoring therapies to each patient’s unique genetic makeup. This approach
